DESIGN, SYNTHESIS, AND EVALUATION OF NOVEL TYROSINASE INHIBITORS FOR SKIN DEPIGMENTATION
DOI:
https://doi.org/10.22159/ijap.2026v18i1.54475Keywords:
Tyrosinase inhibitors, Skin whitening, Molecular docking, In vitro assay, Cinnamic acid, DepigmentationAbstract
Objective: Hyperpigmentation is a prevalent dermatological condition caused by excessive melanin production, primarily catalyzed by the enzyme tyrosinase. Existing depigmenting agents, such as hydroquinone and kojic acid, are limited by cytotoxicity, instability, and suboptimal efficacy. This study aimed to design, synthesize, and evaluate structurally novel tyrosinase inhibitors derived from cinnamic acid to overcome these limitations.
Methods: Tencinnamic acid-based derivatives were designed with strategic modifications, including esterification with hydroquinone and aromatic moieties, to enhance binding affinity and stability. Molecular docking studies were conducted using tyrosinase crystal structures (PDB IDs: 3NQ1 and 5I38) to identify key binding interactions. Six lead compounds were synthesized and structurally characterized via NMR and FTIR spectroscopy. Their tyrosinase inhibitory activity was assessed in vitro using mushroom tyrosinase under standardized assay conditions.
Results: Molecular docking revealed favorable interactions within the tyrosinase active site, with compound 9 exhibiting the highest docking scores. In vitro assays confirmed compound 9 as the most potent inhibitor, with an IC₅₀ value of 31.35 µg/ml, outperforming kojic acid (IC₅₀ = 94.96 µg/ml) and hydroquinone (IC₅₀ = 772.8 µg/ml) under identical conditions.
Conclusion: Compound 9 demonstrated superior tyrosinase inhibition compared to conventional agents, indicating its potential as a safer and more effective alternative for treating hyperpigmentation. These findings support further development of compound 9 for use in topical formulations targeting melasma and related pigmentary disorders, with planned follow-up studies including in vivo efficacy and safety evaluations.
References
1. Zaid Alkilani AZ, Musleh B, Hamed R, Swellmeen L, Basheer HA. Preparation and characterization of patch loaded with clarithromycin nanovesicles for transdermal drug delivery. J Funct Biomater. 2023;14(2):57. doi: 10.3390/jfb14020057, PMID 36826856.
2. Ainger SA, Jagirdar K, Lee KJ, Soyer HP, Sturm RA. Skin pigmentation genetics for the clinic. Dermatology. 2017;233(1):1-15. doi: 10.1159/000468538, PMID 28463841.
3. Bergfelt DR. Anatomy and physiology of the mare. In: Equine breeding management and artificial insemination. Amsterdam: Elsevier; 2009. p. 113-31. doi: 10.1016/B978-1-4160-5234-0.00011-8.
4. Prakash V, Jaiswal N, Srivastava M. A review on medicinal properties of Centella asiatica. Asian J Pharm Clin Res. 2017;10(10):69-74. doi: 10.22159/ajpcr.2017.v10i10.20760.
5. Saadh MJ, Ramirez Coronel AA, Saini RS, Arias Gonzales JL, Amin AH, Gavilan JC. Advances in mesenchymal stem/stromal cell-based therapy and their extracellular vesicles for skin wound healing. Hum Cell. 2023;36(4):1253-64. doi: 10.1007/s13577-023-00904-8, PMID 37067766.
6. Betz G, Aeppli A, Menshutina N, Leuenberger H. In vivo comparison of various liposome formulations for cosmetic application. Int J Pharm. 2005;296(1-2):44-54. doi: 10.1016/j.ijpharm.2005.02.032, PMID 15885454.
7. Yousef H, Alhajj M, Sharma S. Anatomy skin (integument) epidermis. StatPearls; 2017. PMID: 29262154.
8. Chakraborty AK, Funasaka Y, Komoto M, Ichihashi M. Effect of arbutin on melanogenic proteins in human melanocytes. Pigment Cell Res. 1998;11(4):206-12. doi: 10.1111/j.1600-0749.1998.tb00731.x, PMID 9711535.
9. La Berge GS, Duvall E, Grasmick Z, Haedicke K, Galan A, Leverett J. Recent advances in studies of skin color and skin cancer. Yale J Biol Med. 2020;93(1):69-80. PMID 32226338.
10. Sauriasari R, Azizah N, Basah K. Tyrosinase inhibition, 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity and phytochemical screening of fractions and ethanol extract from leaves and stem bark of matoa (Pometia pinnata). Asian J Pharm Clin Res. 2017;10(17):85-9. doi: 10.22159/ajpcr.2017.v10s5.23105.
11. AlJbour ND. An overview of new trends in the cosmetics industry. Int J Appl Pharm. 2025;17(3):136-47. doi: 10.22159/ijap.2025v17i3.53320.
12. Chang TS. An updated review of tyrosinase inhibitors. Int J Mol Sci. 2009;10(6):2440-75. doi: 10.3390/ijms10062440, PMID 19582213.
13. Singh K, Bhushan B, Mittal N, Kushwaha A, Raikwar CK, Sharma AK. Recent advances in enzyme inhibition: a pharmacological review. Curr Enzyme Inhib. 2024;20(1):2-19. doi: 10.2174/0115734080271639231030093152.
14. Kim HD, Choi H, Abekura F, Park JY, Yang WS, Yang SH. Naturally-occurring tyrosinase inhibitors classified by enzyme kinetics and copper chelation. Int J Mol Sci. 2023;24(9):8226. doi: 10.3390/ijms24098226, PMID 37175965.
15. Kim YJ, Uyama H. Tyrosinase inhibitors from natural and synthetic sources: structure inhibition mechanism and perspective for the future. Cell Mol Life Sci. 2005;62(15):1707-23. doi: 10.1007/s00018-005-5054-y, PMID 15968468.
16. Melfi F, Carradori S, Angeli A, D Agostino I. Nature as a source and inspiration for human monoamine oxidase B (hMAO-B) inhibition: a review of the recent advances in chemical modification of natural compounds. Expert Opin Drug Discov. 2023;18(8):851-79. doi: 10.1080/17460441.2023.2226860, PMID 37332199.
17. Hajizadeh M, Moosavi Movahedi Z, Sheibani N, Moosavi Movahedi AA. An outlook on suicide enzyme inhibition and drug design. J Iran Chem Soc. 2022;19(5):1575-92. doi: 10.1007/s13738-021-02416-4.
18. Sanchez Mas J, Hahmann C, Gerritsen I, Garcia Borron JC, Jimenez Cervantes C. Agonist-independent high constitutive activity of the human melanocortin 1 receptor. Pigment Cell Res. 2004;17(4):386-95. doi: 10.1111/j.1600-0749.2004.00160.x, PMID 15250941.
19. Gajos Michniewicz A, Czyz M. WNT signaling in melanoma. Int J Mol Sci. 2020;21(14):4852. doi: 10.3390/ijms21144852, PMID 32659938.
20. Liu T, Xi T, Dong X, Xu D. Research progress on pathogenesis of skin pigmentation in chronic liver disease. Biomol Biomed. 2025;25(6):1218-32. doi: 10.17305/bb.2024.11085, PMID 39689154.
21. Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20(7):781-7. doi: 10.1111/j.1468-3083.2006.01670.x, PMID 16898897.
22. Kapoor DU, Sharma H, Maheshwari R, Pareek A, Gaur M, Prajapati BG. Konjac glucomannan: a comprehensive review of its extraction, health benefits and pharmaceutical applications. Carbohydr Polym. 2024;339:122266. doi: 10.1016/j.carbpol.2024.122266, PMID 38823930.
23. Rubab L. Targeting tyrosinase: heterocyclic compounds in the spotlight. In: Heterocyclic Chemistry-New Perspectives. 2024. p. 45. doi: 10.5772/intechopen.1004439.
24. Gunia Krzyżak A, Sloczynska K, Popiol J, Koczurkiewicz P, Marona H, Pekala E. Cinnamic acid derivatives in cosmetics: current use and future prospects. Int J Cosmet Sci. 2018;40(4):356-66. doi: 10.1111/ics.12471, PMID 29870052.
25. Hassan M, Shahzadi S, Kloczkowski A. Tyrosinase inhibitors naturally present in plants and synthetic modifications of these natural products as anti-melanogenic agents: a review. Molecules. 2023;28(1):378. doi: 10.3390/molecules28010378, PMID 36615571.
26. Juliano CC. Spreading of dangerous skin-lightening products as a result of colourism: a review. Appl Sci. 2022;12(6):3177. doi: 10.3390/app12063177.
27. Kamboj S, Jhawat V, Saini V, Bala S. Recent advances in permeation enhancement techniques for transdermal drug delivery systems: a review. Curr Drug Ther. 2014;8(3):181-8. doi: 10.2174/15748855113086660012.
28. Karkeszova K, Mastihubova M, Mastihuba V. Regioselective enzymatic synthesis of kojic acid monoesters. Catalysts. 2021;11(12):1430. doi: 10.3390/catal11121430.
29. Elliott D. ACCCN’s critical care nursing. 2nd ed. Elsevier Australia; 2011.
30. Al Amin M, Cao J, Naeem M, Banna H, Kim MS, Jung Y. Increased therapeutic efficacy of a newly synthesized tyrosinase inhibitor by solid lipid nanoparticles in the topical treatment of hyperpigmentation. Drug Des Devel Ther. 2016;10:3947-57. doi: 10.2147/DDDT.S123759, PMID 27980392.
31. Kabiri H, Tayarani Najaran Z, Rahmanian Devin P, Vaziri MS, Nasirizadeh S, Golmohammadzadeh S. Preparation, characterization and evaluation of anti-tyrosinase activity of solid lipid nanoparticles containing Undecylenoyl phenylalanine (Sepiwhite®). J Cosmet Dermatol. 2022;21(11):6061-71. doi: 10.1111/jocd.15102, PMID 35593521.
32. Hatem S, Kamel AO, Elkheshen SA, Nasr M, Moftah NH, Ragai MH. Nano-vesicular systems for melanocytes targeting and melasma treatment: in vitro characterization ex-vivo skin retention and preliminary clinical appraisal. Int J Pharm. 2024;665:124731. doi: 10.1016/j.ijpharm.2024.124731, PMID 39306205.
33. Khan HM. Encapsulation of alpha arbutin a depigmenting agent in nanosized ethosomes: in vitro and in vivo human studies. Heliyon. 2023 Aug 23;9(9):e19326. doi: 10.1016/j.heliyon.2023.e19326.
34. Huang X, Chen C, Zhu X, Zheng X, Li S, Gong X. Transdermal BQ-788/EA@ZnO quantum dots as targeting and smart tyrosinase inhibitors in melanocytes. Mater Sci Eng C Mater Biol Appl. 2019;102:45-52. doi: 10.1016/j.msec.2019.04.042, PMID 31147016.
35. Jeyranpour F, Alahyarizadeh G, Arab B. Comparative investigation of thermal and mechanical properties of cross-linked epoxy polymers with different curing agents by molecular dynamics simulation. J Mol Graph Model. 2015;62:157-64. doi: 10.1016/j.jmgm.2015.09.012, PMID 26432014.
36. Abdullah AH, Alarareh AK, Al Sha ER MA, Habashneh AY, Awwadi FF, Bardaweel SK. Docking synthesis and anticancer assessment of novel quinoline-amidrazone hybrids. Pharmacia. 2024;71:1-12. doi: 10.3897/pharmacia.71.e117192.
37. Wang YH, Avonto C, Avula B, Wang M, Rua D, Khan IA. Quantitative determination of α-arbutin β-arbutin kojic acid nicotinamide, hydroquinone resorcinol 4-methoxyphenol 4-ethoxyphenol and ascorbic acid from skin whitening products by HPLC-UV. J AOAC Int. 2015;98(1):5-12. doi: 10.5740/jaoacint.14-123, PMID 25857872.
38. Neeley E, Fritch G, Fuller A, Wolfe J, Wright J, Flurkey W. Variations in IC(50) values with purity of mushroom tyrosinase. Int J Mol Sci. 2009;10(9):3811-23. doi: 10.3390/ijms10093811, PMID 19865520.
39. Phasha V, Senabe J, Ndzotoyi P, Okole B, Fouche G, Chuturgoon A. Review on the use of kojic acid a skin-lightening ingredient. Cosmetics. 2022;9(3):64. doi: 10.3390/cosmetics9030064.
40. Souza PM, Elias ST, Simeoni LA, De Paula JE, Gomes SM, Guerra EN. Plants from Brazilian Cerrado with potent tyrosinase inhibitory activity. PLOS One. 2012;7(11):e48589. doi: 10.1371/journal.pone.0048589, PMID 23173036.
41. Mukattash HK, Issa R, Abu Hajleh MN, Al Daghistani H. Inhibitory effects of polyphenols from Equisetum ramosissimum and Moringa peregrina extracts on Staphylococcus aureus collagenase and tyrosinase enzymes: in vitro studies. Jordan J Pharm Sci. 2024;17(3):530-48. doi: 10.35516/jjps.v17i3.2164.
42. Saadh MJ, Ramirez Coronel AA, Saini RS, Arias Gonzales JL, Amin AH, Gavilan JC. Advances in mesenchymal stem/stromal cell-based therapy and their extracellular vesicles for skin wound healing. Hum Cell. 2023;36(4):1253-64. doi: 10.1007/s13577-023-00904-8, PMID 37067766.
Published
How to Cite
Issue
Section
Copyright (c) 2026 AMANI Y. SALMAN, MANAL M. NAJDAWI, MAHMOUD A. AL-SHA’ER, NAWZAT D. AL JBOUR, RAWANDM DAGHMASH, ANWAR M. HUSSEIN, SULIMAN M. EDEAS, LOAY K. HASSOUNEH, ZEAD H. ABUDAYEH, ALA’ SARHAN, MOHAMMED ALKADERI
This work is licensed under a Creative Commons Attribution 4.0 International License.